A Phase 3 interventional study of hMG subcutaneous injection and Placebo in Infertility (IVF Patients), sponsored by Granata Bio Corporation. Active, not recruiting at 16 sites in United States. Open to female participants aged 18 Years to 42 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Granata Bio Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 395 studies in Infertility with a site in United States — 63 open to participants now, 85 under way, 7 of them phase 3. Infertility · United States.
Among the 395 studies in Infertility with a site in United States, this one is the 22nd largest by planned enrollment of the 274 interventional ones that give a count, is one of 21 that started in 2025, is one of 26 in phase 3, reaches primary completion later than 57 of the 83 other live ones, and was the 380th registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →63 of the 395 studies in Infertility with a site in United States are open now. Recruiting first, the newest first:
Abigail Mancuso · Sites in United States
Ages 18–45
Brigham and Women's Hospital · Sites in United States
Ages 18–40 · Women only · Healthy volunteers
Kevin Doody · Sites in United States
Ages 18–35 · Women only
University of Oklahoma · Sites in United States
Ages 18–45 · Women only
Reproductive Medicine Associates of New Jersey · Sites in United States
Ages 18–42 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 42 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
395 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 32 · Phase 3 31 · Phase 4 35
First in 1989; this study’s year is marked. 21 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 659 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 89 across the 274 interventional studies, 150 across the 119 observational. Of the 251 that completed or were terminated, 57 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 395 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Granata Bio Corporation as lead sponsor.
Granata Bio Corporation has 1 study filed under Infertility — fewer than ten, so there is no comparison to draw.
25 of the studies in Infertility with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06375811Phase 3Yale UniversityPre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp | 2027-03-31 |
| NCT06858111Phase 3Gameto, Inc.Fertilo In Vitro Research Study and Trial | 2027-05 |
| NCT04544462Genomic Prediction Inc.ANXA5 M2 Haplotyping in IVF Patients and Embryos | 2026-11 |
| NCT07083700Inception Fertility Research Institute, LLCFrame Support Study | 2026-12 |
| NCT02573415The Cleveland ClinicUterine Transplantation for the Treatment of Uterine Factor Infertility | 2026-12 |
Add all 25 to your calendar (.ics) → With an account.
Among the 395 studies in Infertility with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this multicenter, randomized, placebo-controlled, double-blind clinical trial is toto evaluate the efficacy and safety of a human menopausal gonadotropin (hMG) in the development of multiple follicles, pregnancy, and cumulative live birth as part of an Assisted Reproductive Technology (ART) cycle in in women with a diagnosis of infertility.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Human Menopausal Gonadotropin, daily subcutaneous injection
Drug: hMG subcutaneous injection
Placebo, daily subcutaneous injection
Drug: Placebo
daily subcutaneous injection
daily subcutaneous injection
cumulative live birth rate
cumulative live birth rate following vitrified-thawed, single-euploid blastocyst transfer(s)
Time frame: 12 months
Positive pregnancy (serum β-human chorionic gonadotropin [hCG])
Time frame: 10 +/-2 days after Embryo transfer
Clinical pregnancy (intrauterine gestational sac with fetal heartbeat)
Time frame: 5 weeks ± 6 days post-embryo transfer
Ongoing pregnancy (intrauterine pregnancy with fetal heartbeat)
Time frame: 10 weeks ± 6 days post-embryo transfer (ET)
Live birth rate
Time frame: 9 months after ET
Number of oocytes retrieved per stimulation cycle
Time frame: 12-22 days after controlled ovarian stimulation start
Number of metaphase II (MII) oocytes retrieved
Time frame: 12-22 days after controlled ovarian stimulation start
Fertilization rate (proportion of MII oocytes with normal fertilization)
Time frame: 12-22 days after Controlled Ovarian stimulation start
Number of Day 5 blastocysts from oocyte retrievals from Period 1 and Period 2
Time frame: 12-22 days after controlled ovarian stimulation start
Total gonadotropin dose required per stimulation cycle
Time frame: 12-20 days after start Controlled ovarian stimulation
Serum estradiol concentration on the day of ovulation trigger
Time frame: 12-20 days after controlled ovarian stimulation start
Serum progesterone (P4) on Day 5 of stimulation
Time frame: 5 days after start controlled ovarian stimulation
Serum Follicular Stimulation Hormone (FSH) level on stimulation day 1, pre-dose
Time frame: 1 day of stimulation
Serum Luteinizing hormone (LH) level on stimulation day 1, pre-dose
Time frame: 1 day of stimulation
Serum human Chorionic Gonadotropin (hCG) level on stimulation day 1, pre-dose
Time frame: 1 day of stimulation
FSH level on stimulation day 1, 1-4 hours post dose
Time frame: 1 day of stimulation
LH level on stimulation day 1, 1-4 hours post dose
Time frame: 1 day of stimulation
hCG level on stimulation day 1, 1-4 hours post dose
Time frame: 1 day of stimulation
FSH level on stimulation day 5
Time frame: After 5 day of stimulation
LH level on stimulation day 5
Time frame: After 5 day of stimulation
hCG level on stimulation day 5
Time frame: After 5 day of stimulation
FSH level on last stimulation day
Time frame: 12-20 days after controlled ovarian stimulation start
LH level on last stimulation day
Time frame: 12-20 days after controlled ovarian stimulation start
hCG level on last stimulation day
Time frame: 12-20 days after controlled ovarian stimulation start
FSH level on oocytes retrieval day
Time frame: 12-22 days after controlled ovarian stimulation start
LH level on oocytes retrieval day
Time frame: 12-22 days after controlled ovarian stimulation start
hCG level on oocytes retrieval day
Time frame: 12-22 days after controlled ovarian stimulation start
Incidence, severity, timing, and duration of treatment-emergent adverse events (TEAEs), including action taken and outcome
Time frame: up to 10 weeks post embryo transfer
Injection sites reactions (e.g., pain, erythema, swelling)
Time frame: 20 days after Controlled ovarian stimulation start
Incidence of early and late ovarian hyperstimulation syndrome (OHSS)
Time frame: up to 10 weeks post Embryo transfer
Development of treatment-emergent anti-drug antibodies
Time frame: up to 5 weeks +/- 6 days after embryo transfer
Singleton live birth
Time frame: 9 months post embryo transfer
Multiple gestations (twins, triplets, or higher-order multifetal pregnancies)
Time frame: 9 months after Embryo transfer
Biochemical pregnancy loss
Time frame: up to 6 weeks after embryo transfer
Ectopic pregnancy
Time frame: Up to 6 weeks after embryo transfer
Early pregnancy loss
Time frame: Up to 12 weeks of gestation
Intrauterine fetal demise
Time frame: up to 9 months after embryo transfer
Incidence of maternal/pregnancy complications
Time frame: up to 9 months after embryo transfer
Preterm birth
Time frame: up to 37 weeks of gestation
Small for gestational age
Time frame: up to 9 months after Embryo transfer
Stillbirth
Time frame: up to 9 months after embryo transfer
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Nov 2028, 36 months after the start.
Of 25 industry-sponsored phase 3 interventional studies under Infertility, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 36 months is above that.
Counting every sponsor, half of 59 studies reached it within 24 months; a quarter within 16 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.